Multiple Sclerosis — Mindfulness Meditation in Treating Insomnia in Multiple Sclerosis
Citation(s)
Abbasi S Ms, Alimohammadi N PhD, Pahlavanzadeh S Ms Effectiveness of Cognitive Behavioral Therapy on the Quality of Sleep in Women with Multiple Sclerosis: A Randomized Controlled Trial Study. Int J Community Based Nurs Midwifery. 2016 Oct;4(4):320-328.
Abrishami A, Khajehdehi A, Chung F A systematic review of screening questionnaires for obstructive sleep apnea. Can J Anaesth. 2010 May;57(5):423-38. doi: 10.1007/s12630-010-9280-x. Epub 2010 Feb 9. Review.
Bamer AM, Johnson KL, Amtmann DA, Kraft GH Beyond fatigue: Assessing variables associated with sleep problems and use of sleep medications in multiple sclerosis. Clin Epidemiol. 2010 May 1;2010(2):99-106.
Bastien CH, Vallières A, Morin CM Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001 Jul;2(4):297-307.
Braley TJ, Segal BM, Chervin RD Obstructive sleep apnea and fatigue in patients with multiple sclerosis. J Clin Sleep Med. 2014 Feb 15;10(2):155-62. doi: 10.5664/jcsm.3442.
Braley TJ, Segal BM, Chervin RD Sleep-disordered breathing in multiple sclerosis. Neurology. 2012 Aug 28;79(9):929-36. doi: 10.1212/WNL.0b013e318266fa9d. Epub 2012 Aug 15.
Brass SD, Li CS, Auerbach S The underdiagnosis of sleep disorders in patients with multiple sclerosis. J Clin Sleep Med. 2014 Sep 15;10(9):1025-31. doi: 10.5664/jcsm.4044.
Britton WB, Haynes PL, Fridel KW, Bootzin RR Polysomnographic and subjective profiles of sleep continuity before and after mindfulness-based cognitive therapy in partially remitted depression. Psychosom Med. 2010 Jul;72(6):539-48. doi: 10.1097/PSY.0b013e3181dc1bad. Epub 2010 May 13.
Cartwright RD Alcohol and NREM parasomnias: evidence versus opinions in the international classification of sleep disorders, 3rd edition. J Clin Sleep Med. 2014 Sep 15;10(9):1039-40. doi: 10.5664/jcsm.4050.
Chiu HY, Chen PY, Chuang LP, Chen NH, Tu YK, Hsieh YJ, Wang YC, Guilleminault C Diagnostic accuracy of the Berlin questionnaire, STOP-BANG, STOP, and Epworth sleepiness scale in detecting obstructive sleep apnea: A bivariate meta-analysis. Sleep Med Rev. 2017 Dec;36:57-70. doi: 10.1016/j.smrv.2016.10.004. Epub 2016 Nov 5. Review.
Clancy M, Drerup M, Sullivan AB Outcomes of Cognitive-Behavioral Treatment for Insomnia on Insomnia, Depression, and Fatigue for Individuals with Multiple Sclerosis: A Case Series. Int J MS Care. 2015 Nov-Dec;17(6):261-7. doi: 10.7224/1537-2073.2014-071.
Dias RA, Hardin KA, Rose H, Agius MA, Apperson ML, Brass SD Sleepiness, fatigue, and risk of obstructive sleep apnea using the STOP-BANG questionnaire in multiple sclerosis: a pilot study. Sleep Breath. 2012 Dec;16(4):1255-65. doi: 10.1007/s11325-011-0642-6. Epub 2012 Jan 21.
Gagnon C, Bélanger L, Ivers H, Morin CM Validation of the Insomnia Severity Index in primary care. J Am Board Fam Med. 2013 Nov-Dec;26(6):701-10. doi: 10.3122/jabfm.2013.06.130064.
Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52.
Lanza G, Ferri R, Bella R, Ferini-Strambi L The impact of drugs for multiple sclerosis on sleep. Mult Scler. 2017 Jan;23(1):5-13. doi: 10.1177/1352458516664034. Epub 2016 Aug 19. Review.
Lee HA, Lee HJ, Moon JH, Lee T, Kim MG, In H, Cho CH, Kim L Comparison of Wearable Activity Tracker with Actigraphy for Sleep Evaluation and Circadian Rest-Activity Rhythm Measurement in Healthy Young Adults. Psychiatry Investig. 2017 Mar;14(2):179-185. doi: 10.4306/pi.2017.14.2.179. Epub 2017 Mar 6.
Martires J, Zeidler M The value of mindfulness meditation in the treatment of insomnia. Curr Opin Pulm Med. 2015 Nov;21(6):547-52. doi: 10.1097/MCP.0000000000000207. Review.
Mendozzi L, Tronci F, Garegnani M, Pugnetti L Sleep disturbance and fatigue in mild relapsing remitting multiple sclerosis patients on chronic immunomodulant therapy: an actigraphic study. Mult Scler. 2010 Feb;16(2):238-47. doi: 10.1177/1352458509354551. Epub 2009 Dec 22.
Reynard AK, Sullivan AB, Rae-Grant A A systematic review of stress-management interventions for multiple sclerosis patients. Int J MS Care. 2014 Fall;16(3):140-4. doi: 10.7224/1537-2073.2013-034.
Siebern AT, Manber R Insomnia and its effective non-pharmacologic treatment. Med Clin North Am. 2010 May;94(3):581-91. doi: 10.1016/j.mcna.2010.02.005. Review.
Tan A, Yin JD, Tan LW, van Dam RM, Cheung YY, Lee CH Predicting obstructive sleep apnea using the STOP-Bang questionnaire in the general population. Sleep Med. 2016 Nov - Dec;27-28:66-71. doi: 10.1016/j.sleep.2016.06.034. Epub 2016 Oct 27.
Van de Water AT, Holmes A, Hurley DA Objective measurements of sleep for non-laboratory settings as alternatives to polysomnography--a systematic review. J Sleep Res. 2011 Mar;20(1 Pt 2):183-200. doi: 10.1111/j.1365-2869.2009.00814.x. Review.
Veauthier C, Paul F Sleep disorders in multiple sclerosis and their relationship to fatigue. Sleep Med. 2014 Jan;15(1):5-14. doi: 10.1016/j.sleep.2013.08.791. Epub 2013 Nov 15. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.